Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Luca Potestio,Angelo Ruggiero,Gabriella Fabbrocini,Fabrizio Martora,Matteo Megna
DOI: https://doi.org/10.2147/PTT.S407647
2023-05-04
Psoriasis: Targets and Therapy
Abstract:Luca Potestio, &ast Angelo Ruggiero, &ast Gabriella Fabbrocini, Fabrizio Martora, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy &astThese authors contributed equally to this work Correspondence: Luca Potestio, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, Tel +39 - 81 -7462457, Fax +39 - 081 - 7462442, Email Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of biological drugs and small molecules revolutionized the treatment options showing promising results in terms of safety and effectiveness, some limitations remain. Thus, there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. In this scenario, deucravacitinib, an oral small molecule which selectively inhibits Tyrosine Kinase 2, may represent a promising weapon in psoriasis management. The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis. Keywords: deucravacitinib, psoriasis, JAK inhibitors, TYK2 inhibitors Psoriasis is a chronic inflammatory skin condition, with a worldwide prevalence of about 3%. 1 Plaque psoriasis is the most frequent disease form, accounting for up to 90% of cases and being clinically characterized by sharply demarcated erythematous plaques covered by silvery-white lamellar scales. 2 Several comorbidities may be associated with psoriasis such as metabolic syndrome (diabetes, obesity, hypertension, dyslipidemia), psoriatic arthritis, cardiovascular disease, nonalcoholic fatty liver disease, inflammatory bowel disease, and depression. 1,3,4 Moreover, psoriasis strongly affects patients' quality of life. 5 Thus, an effective and personalized treatment is needed. 6 In this scenario, even if mild psoriasis is often controlled with topical therapies, systemic treatments are required for moderate-to-severe forms. 7 However, traditional systemic treatments (cyclosporine, acitretin, methotrexate, fumarates) are often avoided for contraindications (eg cardiovascular disease, renal or hepatic failure, etc.) or for the risk of adverse events (AEs). 8,9 Phototherapy may be a therapeutic opportunity, but it is limited by logistic concerns. 8,9 Recently, the introduction of small molecules (apremilast) and biologic drugs targeting different cytokines [tumor necrosis factor (TNF) α, interleukin (IL)-12/23,-17,-23] revolutionized the management of psoriasis showing promising results in terms of efficacy and safety. 10–16 However, unmet needs or some limitations may still remain. On one hand, even if apremilast does not require parental administration, it shows lower and slower effectiveness compared to biologics with possible gastrointestinal AEs. 17,18 On the other hand, biologic drugs require parental administration, which may be linked to increased risk of infection (upper respiratory tract infection) with some biologics being contraindicated in certain condition (eg multiple sclerosis for anti-TNF and inflammatory bowel diseases for anti-IL17). Finally, both apremilast and biologics have high costs and may present variable degree of risk of loss of efficacy over time. 17,18 Thus, there is still a need for accessible, effective, and safe oral drugs for patients with moderate-to-severe forms of psoriasis. In this context, deucravacitinib, a recently developed oral small molecule (OSM) that selectively inhibits Tyrosine Kinase 2 (TYK2), may represent a valuable weapon in psoriasis management. 19,20 The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis. Literature research on the PubMed, clinicaltrials.gov, Cochrane Skin and Embase databases (until February 16, 2023) was carried out. Manuscripts were found, screened and analyzed for relevant data following the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines (Figure 1). 21 The following keywords were used for the research: "psoriasis", "oral small molecules", "deucravacitinib", "efficacy", "safety". Investigated manuscripts included reviews, metanalyses, clinical trials, real-life experiences, case reports and series. The most relevant articles were selected. Manuscript -Abstract Truncated-